6 Drugs Approved Despite Failed Trials or Minimal Data

In recent years, the FDA has granted approval to some novel drugs despite failed clinical trials or minimal evidence. Guidance issued in rare or uniformly fatal diseases like amyotrophic lateral sclerosis and the approvals of Aduhelm in Alzheimer’s and Qalsody in ALS indicate a trend toward greater regulatory flexibility.